GP96 C-terminal improves Her2/neu DNA vaccine

Journal of Gene Medicine

Volumn 12, Issue 4, 2010, Pages 345-353

  Pakravan, Nafiseh ^a   Soleimanjahi, Hoorieh ^a   Hassan, Zuhair Mohammad ^a  

^a TARBIAT MODARES UNIVERSITY   (Iran)

Author keywords

DNA vaccine; Fusion co administration; GP96; Her2; Immunotherapy; Regulatory T cell

Indexed keywords

CYTOKINE; DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; GLYCOPROTEIN GP 96; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CD4+ CD25+ T LYMPHOCYTE; CELL ACTIVATION; CELL MATURATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DNA IMMUNIZATION; DRUG EFFICACY; FEMALE; IMMUNE RESPONSE; MOUSE; NEOPLASM; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE NEU; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR CELL; TUMOR LOCALIZATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CELL LINE, TUMOR; FLOW CYTOMETRY; GENETIC VECTORS; HUMANS; INTERFERON-GAMMA; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; RATS; RECEPTOR, ERBB-2; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; VACCINATION; VACCINES, DNA;

EID: 77950908268     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1445     Document Type: Article

References (48)

1. Disis ML, Calenoff E, McLaughlin G, et al. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 1994; 54: 16-20. (Pubitemid 24042079)
2. Fisk B, Hudson JM, Kavanagh J, et al. Existent proliferative responses of peripheral blood mononuclear cells from healthy donors and ovarian cancer patients to HER-2 peptides. Anticancer Res 1997; 17: 45-53. (Pubitemid 27116644)
3. Crone SA, Zhao YY, Fan L, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002; 8: 459-465. (Pubitemid 34546747)
4. Houghton AN, Lloyd KO. Stuck in the MUC on the long and winding road. Nat Med 1998; 4: 270-271. (Pubitemid 28144078)
5. Piechocki MP, Pilon SA, Wei WZ. Complementary antitumor immunity induced by plasmid DNA encoding secreted and cytoplasmic human erbb-2. J Immunol 2001; 167: 3367.
6. Reilly RT, Machiels JP, Emens LA, et al. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradicationof HER-2/neuexpressing tumors. Cancer Res 2001; 61: 880-883.
7. Forni G, Fujiwara H, Martino F, et al. Helper strategy in tumor immunology: expansion of helper lymphocytes and utilization of helper lymphokines for experimental and clinical immunotherapy. Cancer Metastasis Rev 1988; 7: 289-309.
8. Pericle F, Giovarelli M, Colombo MP, et al. An efficient Th-2-type memory follows CD8+ lymphocyte driven and eosinophil mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4. J Immunol 1994; 153: 5659-5673. (Pubitemid 24377702)
9. Gurunathan S, Wu CY, Freidag BL, Seder RA. DNA vaccines: a key for inducing long-term cellular immunity. Curr Opin Immunol 2000; 12: 442-447. (Pubitemid 30410351)
10. Amici A, Smorlesi A, Noce G, et al. DNA vaccination with full-length or truncated neu induces protective immunity against the development of spontaneous mammary tumors inHER-2/neu transgenic mice. Gene Ther 2000; 7: 703-706. (Pubitemid 30255775)
11. Chen Y, Hu D, Eling DJ, Robbins J, Kipps TJ. DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors. Cancer Res 1998; 58: 1965-1971. (Pubitemid 28217474)
12. Curcio C, Di Carlo E, Clynes R, et al. Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. J Clin Invest 2003; 111: 1161-1170. (Pubitemid 36519933)
13. Disis ML, Scholler N, Dahlin A, et al. Plasmid-based vaccines encoding rat neu and immune stimulatory molecules can elicit rat neu-specific immunity. Mol Cancer Ther 2003; 2: 995-1002.
14. Foy TM, Bannink J, Sutherland RA, et al. Vaccination with Her-2/neu DNA or protein subunits protects against growth of a Her-2/neu-expressing murine tumor. Vaccine 2001; 19: 2598-2606. (Pubitemid 32234278)
15. Renard V, Sonderbye L, Ebbehøj K, et al. HER-2 DNA and protein vaccines containing potent Th cell epitopes induce distinct protective and therapeutic antitumor responses in HER-2 transgenic mice. J Immunol 2003; 171: 1588-1595. (Pubitemid 36900095)
16. Rovero S, Amici A, Carlo ED, et al. DNA vaccination against rat Her-2/neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 2000; 165: 5133-5142.
17. Cappello P, Triebel F, Iezzi M, et al. LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice. Cancer Res 2003; 63: 2518-2525. (Pubitemid 36605192)
18. Chang SY, Lee KC, Ko SY, Ko HJ, Kang CY. Enhanced efficacy of DNA vaccination against Her-2/neu tumor antigen by genetic adjuvants. Int J Cancer 2004; 111: 86-95.
19. Dela Cruz JS, Morrison SL, Penichet ML. Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3- (IL-2) or anti-HER2/neu IgG3- (GM-CSF) fusion protein. Vaccine 2005; 23: 4793-4803.
20. Kim JH, Majumder N, Lin H, Chen J, Falo LD Jr, You Z. Enhanced immunity by NeuEDhsp70 DNA vaccine is needed to combat an aggressive spontaneous metastatic breast cancer. Mol Ther 2005; 11: 941-949. (Pubitemid 40724113)
21. Lin CC, Chou CW, Shiau AL, et al. Therapeutic HER2/Neu DNA vaccine inhibits mouse tumor naturally overexpressing endogenous neu. Mol Ther 2004; 10: 290-301.
22. Orlandi F, Venanzi FM, Concetti A, et al. Antibody and CD8+ T cell responses against HER2/neu required for tumor eradication after DNA immunization with a Flt-3 ligand fusion vaccine. Clin Cancer Res 2007; 13: 6195-6203. (Pubitemid 350075081)
23. Quaglino E, Mastini C, Iezzi M, et al. The adjuvant activity of BAT antibody enables DNA vaccination to inhibit the progression of established autochthonous Her-2/neu carcinomas in BALB/c mice. Vaccine 2005; 23: 3280-3287. (Pubitemid 40523121)
24. Spadaro M, Ambrosino E, Iezzi M, et al. Cure of mammary carcinomas in Her-2 transgenic mice through sequential stimulation of innate (neoadjuvant interleukin-12) and adaptive (DNA vaccine electroporation) immunity. Clin Cancer Res 2005; 11: 1941-1952 (Pubitemid 40471860)
25. Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 2002; 20: 395-425. (Pubitemid 34293430)
26. Hsu KF, Hung CF, Cheng WF, et al. Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen. Gene Ther 2001; 8: 376-383.
27. Baker-LePain JC, Sarzotti M, Nicchitta CV. Glucose-regulated protein 94/glycoprotein 96 elicits bystander activation of CD4(+) T cell Th1 cytokine production in vivo. J Immunol 2004; 172: 4195-4203. (Pubitemid 38375232)
28. Li HT, Yan JB, Li J, et al. Enhancement of humoral immune responses to HBsAg by heat shock protein GP96 and its N-terminal fragment in mice. World J Gastroenterol 2005; 11: 2858-2863. (Pubitemid 40790051)
29. Rapp UK, Kaufmann SH. DNA vaccination with GP96-peptide fusion proteins induces protection against an intracellular bacterial pathogen. Int Immunol 2004; 16: 597-605.
30. Yan J, Liu X, Wang Y, et al. Enhancing the potency of HBV DNA vaccines using fusion genes of HBV-specific antigens and the N-terminal fragment of GP96. J Gene Med 2007; 9: 107-121. (Pubitemid 46444488)
31. Sambrook J, Russell DW. Molecular Cloning: A Laboratory Manual, 3rd edn, Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, 2001.
32. Nagata Y, Furugen R, Hiasa A, et al. Peptides derived from a wild-type murine protooncogene c-erbB-2/HER2/2 neu can induce CTL and tumor suppression in syngeneic hosts. J Immunol 1997; 159: 1336-1343. (Pubitemid 127484112)
33. Li Z, Menoret A, Srivastava P. Roles of heat-shock proteins in antigen presentation and cross-presentation. Curr Opin Immunol 2002; 14: 45-51. (Pubitemid 34085106)
34. Banerjee PP, Vinay DS, Mathew A, et al. Evidence that glycoprotein 96 (B2), a stress protein, functions as a Th2-specific costimulatory molecule. J Immunol 2002; 169: 3507-3518.
35. Doody AD, Kovalchin JT, Mihalyo MA, Hagymasi AT, Drake CG, Adler AJ. Glycoprotein 96 can chaperone both MHC class I- and class II-restricted epitopes for in vivo presentation, but selectively primes CD8+ T cell effector function. J Immunol 2004; 172: 6087-6092.
36. Binder RJ, Vatner R, Srivastava P. The heat-shock protein receptors: some answers and more questions. Tissue Antigens 2004; 64: 442-451. (Pubitemid 39312725)
37. Chow YH, Chiang BL, Lee YL, et al. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes. J Immunol 1998; 160: 1320-1329.
38. Haupt K, Siegel F, Lu M, et al. Induction of a cellular and humoral immune response against preprocalcitonin by genetic immunization: a potential new treatment for medullary thyroid carcinoma. Endocrinology 2001; 142: 1017-1023. (Pubitemid 32202809)
39. Chang DZ, Lomazow W, Joy Somberg C, Stan R, Perales MA. Granulocyte-macrophage colony stimulating factor: an adjuvant for cancer vaccines. Hematology 2004; 9: 207-215. (Pubitemid 38997060)
40. Olson BM, McNeel DG. Methods for constructing and evaluating antitumor DNA vaccines. Methods Mol Biol 2009; 542: 211-243.
41. Di Rosa F, Matzinger P. Long-lasting CD8 T cell memory in the absence of CD4 T cells or B cells. J Exp Med 1996; 183: 2153-2163. (Pubitemid 26158907)
42. Wang B, Norbury CC, Greenwood R, Bennink JR, Yewdell JW, Frelinger JA. Multiple paths for activation of naive CD8+ T cells: CD4-independent help. J Immunol 2001; 167: 1283-1289. (Pubitemid 32703123)
43. Raulet DH, Guerra N. Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat Rev Immunol 2009; 9: 568-580.
44. Nizar S, Copier J, Meyer B, et al. T-regulatory cell modulation: the future of cancer immunotherapy? Br J Cancer 2009; 100: 1697-1703.
45. Lutsiak ME, Tagaya Y, Adams AJ, Schlom J, Sabzevari H. Tumor-induced impairment of TCR signaling results in compromised functionality of tumor-infiltrating regulatory T cells. Immunology 2008; 180: 5871-5881.
46. Amici A, Venanzi FM, Concetti A. Genetic immunizationagainst neu/erbB2 transgenic breast cancer. Cancer Immunol Immunother 1998; 47: 183-190. (Pubitemid 29009672)
47. Schuler T, Qin Z, Ibe S, Noben-Trauth N, Blankenstein T. T helper cell type 1-associated and cytotoxic T lymphocyte-mediated tumor immunity is impaired in interleukin 4-deficient mice. J Exp Med 1999; 189: 803-810. (Pubitemid 29189685)
48. Yang Y, Huang CT, Huang X, Pardoll DM. Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol 2004; 5: 508-515. (Pubitemid 38660463)